Citadel Advisors
TRIB

Citadel Advisors’s Trinity Biotech TRIB Stock Holding History

Citadel Advisors’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,200
Closed -$8.86K – 14243
2025
Q4 		$8.86K Buy
+11,200
New +$11K ﹤0.01% 12437
2024
Q3 		– Sell
-20
Closed -$41 – 15270
2024
Q2 		$41 Buy
+20
New +$39 ﹤0.01% 14116
2023
Q3 		– Sell
-20
Closed -$97 – 15122
2023
Q2 		$97 Hold
20
– – ﹤0.01% 14223
2023
Q1 		$94 Buy
+20
New +$103 ﹤0.01% 14592
2021
Q3 		– Sell
-4,460
Closed -$66K – 14666
2021
Q2 		$66K Sell
4,460
-2,480
-36% -$41.3K ﹤0.01% 13204
2021
Q1 		$130K Buy
+6,940
New +$167K ﹤0.01% 12204

Other funds holding TRIB

HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return
YAG
Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.37B AUM 19.97% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BCM
Becker Capital Management Portland, Oregon $3.4B AUM 24.68% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors's TRIB Position: Q4 2025 in Review

Citadel Advisors sold out of Trinity Biotech (TRIB) in Q4 2025, closing a stake of 39,384 shares — an estimated $38.7K sold.

Citadel Advisors first reported a position in TRIB in Q4 2013 and held it in 21 quarters. The position peaked at $892K in Q1 2015. 27 funds tracked by Wall St. Rank hold TRIB as of Q4 2025.

  • Citadel Advisors reported no remaining Trinity Biotech position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 39,384 Trinity Biotech shares in Q4 2025, an estimated $38.7K.
  • Citadel Advisors first reported a position in Trinity Biotech in Q4 2013 and held it in 21 quarters.
  • Citadel Advisors's Trinity Biotech position peaked at $892K in Q1 2015.
  • 27 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.